synergy nash tirzepatide in Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial Eli Lilly's tirzepatide shows promise

It acts as a GLP-1 receptor agonist, mimicking the hormone glucagon-like peptide-1 (GLP-1), which regulates appetite and blood sugar levels by affecting insulin and glucagon production

Quality & Sourcing For researchers requiring tirzepatide as a reference standard or mechanistic tool, documentation quality is essential for reproducible science

Exercise Regularly: Moderate exercise can strengthen the heart and improve overall cardiovascular health, but patients should follow their doctors advice on what type of exercise is safe for them

Prochlorperazine (510 mg) represents another option, though it carries risks of extrapyramidal side effects

The SELECT trial showed a 20% MACE reduction